文献速递乳腺癌

ER+乳腺癌新辅助试验:加速药物研发与发现的工具

Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.
PubMed 文献 · Cancer Discov · 2017-05-11

综述探讨新辅助内分泌治疗在ER+/HER2-乳腺癌药物开发中的价值,指出该平台可用于研究性药物开发、新组合排序、生物标志物验证及耐药机制发现,但缺乏经过验证的长期疗效替代指标。

要点

  • 新辅助内分泌治疗是ER+/HER2-乳腺癌研究性药物开发的优良平台。
  • 该平台可用于新组合排序、生物标志物验证和耐药机制发现。
  • ER+乳腺癌新辅助试验面临缺乏验证的长期疗效替代指标的挑战。

核心结论

  • 新辅助内分泌治疗是研究性药物开发、新组合排序、生物标志物验证和耐药机制发现的优良平台。
  • 本综述总结了该方法的临床和研究益处,重点是如何将预测性生物标志物最佳整合到新型临床试验设计中。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 新辅助治疗试验为乳腺癌药物开发和发现提供了优良策略,尤其在三阴性型和HER2过表达亚型中,病理完全缓解是长期患者获益的良好替代指标。
  • 在ER+乳腺癌中,由于缺乏经过验证的长期疗效替代指标以及该亚型大多数患者总体预后良好,使用该策略具有挑战性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER+) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype. We review below the clinical benefits of neoadjuvant endocrine therapy for ER+/HER2-negative breast cancer, its use and limitations for drug development, prioritization of adjuvant and metastatic trials, and biomarker discovery.Significance: Neoadjuvant endocrine therapy is an excellent platform for the development of investigational drugs, triaging of novel combinations, biomarker validation, and discovery of mechanisms of drug resistance. This review summarizes the clinical and investigational benefits of this approach, with a focus on how to best integrate predictive biomarkers into novel clinical trial designs. Cancer Discov; 7(6); 561-74. ©2017 AACR.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Guerrero-Zotano AL, Arteaga CL. Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. Cancer Discov. 2017. PMID: 28495849. doi:10.1158/2159-8290.CD-17-0228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。